BIO PRODUCTS
SunBio’s technology and PEG products have been instrumental in the success of several marketed biopharmaceuticals and medical devices. A summary of both launched and pipeline products is provided in the table below.
| Product/Candidate | Status | Literature | |
|---|---|---|---|
| Biopharma | PEG-filgrastim (Brand Name : Ennumo, Pelgraz, Lapelga) |
Approved and marketed in Canada (2018) Approved and marketed in EU (2018) Approved and marketed in Australia (2022) Approved and marketed in Mexico (2022) Approved and marketed in the USA (2026) |
• Efectiveness and safety of pegylated flgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany
• Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim (PELGRAZ)
• Primary Prophylaxis Lapelga® in Early Breast Cancer:A Real-World Experience
|
| SBX (a blood substitute) | Preclinical |
• Efficacy of Pre-Treatment of a Hemoglobin-based Oxygen Carrier in a Rat Permanent MCAO Model of Ischemic Stroke
|
|
| X-PEG-PAL (a novel PEG-phenylalanine ammonia lyase to treat phenylketonuria) | Preclinical | - | |
| X-PEG-uricase (a PEG-uricase to treat gout) | Preclinical | - | |
| LNP (a novel mRNA vaccine delivery) | Preclinical | - | |
| Medical Device | MucoPEG (xerostomia treatment) | FDA approved (2019) Filing for approval in Japan (2025) Filing for approval in a region in China (2025) |
Clinical Evaluation of a Polyethylene Glycol Derivative Rinse for Xerostomia
|
| SynoGel (a stem cell delivery device) | Preclinical | - | |
| PEG Products | Manufacture and Sales | Marketed (1998) | - |